| ¿µ¹® | antihypertensive drug | ÇÑ±Û | °íÇ÷¾Ð¾à, Ç×°íÇ÷¾ÐÁ¦ |
|---|---|---|---|
| ¼³¸í | °íÇ÷¾ÐÀÇ Ä¡·á¿¡ »ç¿ëÇÏ¸ç ³ôÀº Ç÷¾ÐÀ» ³·Ãß´Â ¾à¹°À» ¸»ÇÑ´Ù. °íÇ÷¾Ð¾à¿¡´Â Ç÷°üÆòȰ±Ù¿¡ Á÷Á¢ ÀÛ¿ëÇÏ¿© À̿ϽÃŰ´Â Ç÷°üÈ®ÀåÁ¦(È÷µå¶ó¶óÁø), ±³°¨½Å°æÀÇ È°µ¿À» ¾îµð¼±°¡ Â÷´ÜÇÏ´Â ¾à¹°(·¹¼¼¸£ÇÉ, ¸ÞÆ¿µµÆÄ, ÇÁ·ÎÇÁ¶ó³ë·Ñ), ÀÌ´¢Á¦(ÇÁ·Î¼¼¹Ìµå, ¿¡Å¸Å©¸°»ê)ÀÌ »ç¿ëµÈ´Ù. |
||
| ¿µ¹® | antimalarial drug | ÇÑ±Û | ¸»¶ó¸®¾Æ¾à, Ç׸»¶ó¸®¾ÆÁ¦ |
|---|---|---|---|
| ¼³¸í | ¸»¶ó¸®¾Æ Ä¡·á¿¡ ¾²´Â ¾à. Ű´Ï³×, Ŭ·Î·ÎÄý, ÇÁ¸®¸¶Äý µûÀ§°¡ ÀÖ´Ù. ¸»¶ó¸®¾Æ ¿øÃæÀÇ ¹ßÀ°Áֱ⿡ ´ëÀÀÇØ¼ ¾à¹°ÀÌ ÀÖÀ¸³ª ´ëºÎºÐÀº º´¿ë¿ä¹ý¿¡ µû¶ó¼ ¸»¶ó¸®¾Æ Ä¡·á¸¦ ÇÑ´Ù. ¸ð±â¿¡ ÀÇÇÑ Æ÷ÀÚü°¨¿°¿¡ ´ëÇÑ Çׯ÷ÀÚü ¾àÀº µ¶¼º µîÀÇ ¹®Á¦°¡ ÀÖ¾î¼ ¾ÆÁ÷ ¾ø´Ù. ÀûÇ÷±¸³»¿¡¼ÀÇ È¯»óü, ¹ø½Äü¿¡¸¸ ÀÛ¿ëÇÏ´Â °Í(Ç×¹ø½Äü ¾àÀº Ŭ·Î·ÎÄý, ÇǸ®¸ÞŸ¹Î, Ŭ·Î·Î±¸¾Æ³ªÀ̵å, Ű´Ï³×)Àº ÀûÇ÷±¸ ¿ÜÀÇ ¹ßÀ°Àº ¾ïÁ¦ÇÏÁö ¾ÊÀ¸¹Ç·Î °¨¿°À» ¿ÏÀüÈ÷ ÀúÁöµÇÁö ¾Ê´Â´Ù. ÀûÇ÷±¸³»¿ÜÀÇ ¿øÃæ¿¡ ÀÛ¿ëÇØ ¿ÏÀüÈ÷ °¨¿°À» ¾ïÁ¦ÇÏ´Â °Í(ÆÄ¸¶Å², ÆæÅ¸Å², ÇÁ¸®¸¶Å²), Ç÷ÁßÀÇ »ý½Äü¸¦ Á×ÀÌ´Â °Í(´ëºÎºÐÀÇ Ç׸»¶ó¸®¾ÆÁ¦)Àº ¸ð±â¿¡ ÀÇÇÑ Å¸ÀÎÀ¸·ÎÀÇ Àü¿°¿øÀº ²÷±â´Âµ¥ ȯÀÚÀÚ½ÅÀÇ Áõ»óÀº º¯ÈÇÏÁö ¾Ê´Â´Ù. |
||
| ¿µ¹® | drug | ÇÑ±Û | ¾à, ¾à¹°, ¾àÁ¦ |
|---|---|---|---|
| ¼³¸í | 1. º´, ±âŸ º´Àû »óÅÂÀÇ Áø´Ü, Ä¡·á, ¿¹¹æÀ̳ª °íÅëÀÇ °æ°¨, ¶Ç´Â »ý¸®Àû, º´¸®Àû »óŸ¦ È£Àü½ÃŰ´Â °ÍÀ» ¸ñÀûÀ¸·Î »ç¶÷ ¶Ç´Â µ¿¹°¿¡ Åõ¿©µÇ´Â ÈÇÕ¹°. ¾à¸®Çп¡¼´Â Ä¡·á¾à¸¸ÀÌ ¾Æ´Ï¶ó, »ýü¿¡ ÁÖ¾îÁ³À» ¶§ ¾î¶°ÇÑ ¹ÝÀÀÀ» ³ªÅ¸³»´Â ÈÇй°Áú ¸ðµÎ¸¦ ¾à¹°À̶ó°í ÇÑ´Ù. ÀÛ¿ëÀÌ °ÇÏ°í ¾ÈÀü¼ºÀÌ ³·Àº ¼ø¼·Î µ¶¾à-±Ø¾à-º¸Åë¾àÀ¸·Î ±¸ºÐÇϰí ÀÖ´Ù. ¾à¹°Ä¡·á¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÀÎÀڷμ, »ýüÂÊ ÀÎÀڷδ °³Ã¼Â÷, ¿¬·É, üÁß µîÀÌ ÀÖ°í, ¾à¹°ÂÊ ÀÎÀڷμ´Â Åõ¿©¹æ¹ý, Åõ¿©·®, º´¿ëµÇ°í ÀÖ´Â ´Ù¸¥ ¾à¹° µîÀÌ ÀÖ´Ù. 2. ¾àÀÇ Àç·á°¡ µÇ´Â ¹°Áú. 3. ¿©·¯ °¡Áö ¾àÀ縦 ¼¯¾î Á¶Á¦ÇÑ ¾à. |
||
| ¿µ¹® | drug resistance | ÇÑ±Û | ¾à¹°³»¼º |
|---|---|---|---|
| ¼³¸í | 1. ÈÇпä¹ýÁ¦³ª Ç×»ý¹°ÁúÀÇ ¾î¶² ÀÏÁ¤ ³óµµ·Î ¼¼±ÕÀ» Á×À̰ųª Áõ½ÄÀúÇØ¸¦ ¹Þ´Â °ÍÀ» ÀÌ ÈÇпä¹ýÁ¦³ª Ç×»ý¹°Áú¿¡ °¨¼ö¼ºÀÌ ÀÖ´Ù°í Çϴµ¥, ÀÌ °¨¼ö¼ºÀÌ ¾ø°Ô µÈ »ýŸ¦ ÀúÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. µû¶ó¼ º¯À̹̻ý¹°ÀÇ ¾àÁ¦¿¡ ´ëÇÑ ÀÚÇ×¼ºÀ̶óµç°¡ ³»¼ºÀ̶ó°í ¸»ÇÑ´Ù. 2. ÀǾàǰÀ» °è¼Ó º¹¿ëÇϸé Á¡Â÷ Áõ·®ÇÏÁö ¾ÊÀ¸¸é È¿·ÂÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¼ºÁú. ÀÌ·¯ÇÑ ¶§¸¦ ¾àÁ¦³»¼ºÀÌ »ý°å´Ù°í ÇÑ´Ù. ¸ðµç ¹Ì»ý¹°Àº °¨¼ö¼ºÀ» °¡Áö´Â ¾à¹°¿¡ ÀÇÇÏ¿© »ç¸êµÇÁö¸¸, ¼Ò¼öÀÇ °ÍÀº »ì¾Æ³²¾Æ ±×°ÍÀÌ ÁøÈµÊÀ¸·Î½á »ç¸êÇÏÁö ¾Ê´Â ¼ö°¡ ÀÖ´Ù. ¶Ç, ÃÖÃÊ¿¡´Â °¨¼ö¼ºÀ» °¡Áö°í ÀÖ´ø ±ÕÀÌ Â÷Â÷ ³»¼º±ÕÀ¸·Î µÇ±âµµ ÇÑ´Ù. ¸¹Àº º´¿ø±ÕÀº °¨¼ö¼ºÀÌ ÀÖ´Â ÀǾàǰ¿¡ ´ëÇÏ¿© ³»¼ºÀÌ »ý±ä´Ù. °¡Àå °íµµÀÇ ³»¼º±ÕÀÌ »ý±â±â ½¬¿î °ÍÀº ½ºÆ®·¾Å丶À̽ÅÀε¥ °áÇÙ±Õ°ú ±×¶÷À½¼º±Õ¿¡ ´ëÇÏ¿© ½±°Ô ³»¼ºÀÌ »ý±ä´Ù. Æä´Ï½Ç¸°À̳ª Åׯ®¶ó½ÃŬ¸°(¾ÆÅ©·Î¸¶À̽Å) µîÀÇ Ç×»ý¹°Áúµµ ³»¼ºÀÌ »ý±â±â ½¬¿ì¹Ç·Î, »ç¿ëÇÒ ¶§´Â ÀûÀÀÀ» Àß È®ÀÎÇÏ¿© Çʿ䷮À» Á¤ÇÏ°í ¿¬¿ëÀ» ÇÇÇÑ´Ù. °°Àº È¿°ú°¡ ÀÖ´Â ´Ù¸¥ Á¾·ùÀÇ ¾àÁ¦¸¦ ¼Ò·®¾¿ 2, 3Á¾ º´¿ëÇÏ¸é ³»¼ºÀÇ ¹ß»ýÀÌ Å©°Ô ¾ïÁ¦µÈ´Ù´Â °ÍÀÌ ¾Ë·ÁÁ® ÀÖ´Ù. °áÇÙ¾àÀ¸·Î¼ ½ºÆ®·¾Å丶À̽Űú ÆÄ½º, ¶Ç´Â À̼ҴϾÆÁöµå¸¦ º´¿ëÇÏ´Â °Í µîÀÌ ±× ¿¹ÀÌ´Ù. |
||
| ¿µ¹® | drug dependence | ÇÑ±Û | ¾à¹°ÀÇÁ¸(¼º) |
|---|---|---|---|
| ¼³¸í | ¾î¶² Á¾·ùÀÇ ¾à¹°À» ¹Ýº¹Çؼ »ç¿ëÇÏ´Â µ¿¾È ±× ¾àÀÇ »ç¿ëÀ» ÁßÁöÇÒ ¼ö ¾ø°Ô µÇ´Â »óÅÂ. ÀÇÁ¸ÀÇ Á¤µµ°¡ ½ÉÇØÁö¸é ¾à ¾øÀÌ´Â »ýȰÇÒ ¼ö ¾ø´Â »óÅ¿¡ ºüÁö°í, ±× °á°ú ¹ýÀ» ¾î±â¸é¼±îÁö ¾àÀ» ±¸ÀÔÇÏ°Ô µÈ´Ù. ÀÌÀü¿¡´Â ¾à¹°¸¸¼ºÁßµ¶, ¾à¹°³²¿ë, ¾à¹°½À°ü¼ºÀ̶ó´Â °³³äÀ¸·Î ³ª´©¾îÁ® ÀÖ¾úÁö¸¸, WHO¿¡¼´Â À̰͵éÀ» ¸ðµÎ Æ÷ÇÔ½ÃÄѼ ¾à¹°ÀÇÁ¸À̶ó ÇÏ¿´´Ù. »óÅ¿¡ ÀÇÇÑ ºÐ·ù¶ó ¾à¹°ÀÛ¿ë¿¡ ÀÇÇÑ ºÐ·ù°¡ ÀÖ´Ù. »óÅ¿¡ ÀÇÇÑ °ÍÀº 1.Á¤½ÅÀû ÀÇÁ¸: ¾à¹°ÀÇ »ç¿ëÀ» ÁßÁöÇÏ¸é ºÒ¾È°¨-¿ì¿ï°¨-ÃÊÁ¶°¨ µîÀÇ ½É¸®ÀûÀÎ Áõ»óÀÌ ³ªÅ¸³ª ´Ù½Ã ¾à¹°À» ã°Ô µÇ´Â °æ¿ì. ¾àÀ» ²÷¾úÀ» °æ¿ì¿¡ ³ªÅ¸³ª´Â ½ÅüÁõ»óÀÎ ±Ý´ÜÁõ»óÀº ³ªÅ¸³ªÁö ¾ÊÀ¸¸ç, ¾à¹°ÀÇ Áö¼ÓÀû º¹¿ë¿¡ ÀÇÇØ¼ Á¡Â÷ ¾à¹°¿¡ ´ëÇÑ ½ÅüÀÇ ¹ÝÀÀÀÌ ÁÙ¾îµå´Â Çö»óÀÎ ¾à¹°ÀÇ ³»¼ºµµ ³ªÅ¸³ªÁö ¾Ê´Â´Ù. 2.½ÅüÀû ÀÇÁ¸: ¾à¹° »ç¿ëÀ» ÁßÁöÇÏ¸é ½ÅüÀûÀÎ Àå¾Ö, Áï ±Ý´ÜÁõ»óÀ» ÀÏÀ¸Å°°í ±× °íÅëÀ» ´Þ·¡±â À§ÇØ ¾à¹°À» ã°Ô µÇ´Â °æ¿ìÀÌ´Ù. ´ëºÎºÐ ³»¼ºÀÌ ³ªÅ¸³ª´Âµ¥ °³º°ÀûÀ¸·Î ³ªÅ¸³ª´Â °æ¿ìµµ ÀÖÁö¸¸ ÁÖ·Î º´ÇàÇØ¼ ³ªÅ¸³´Ù. |
||
| ECG | Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ = EKG 1. Conducting System Structu... |
|---|---|
| AER | abduction/external rotation; acoustic evoked response; acute exertional rhabdomyolysis; agranular en... |
| SR | sarcoplasmic reticulum; saturation recovery; scanning radiometer; screen; secretion rate; sedimentat... |
| MPD | main pancreatic duct; maximum permissible dose; mean population doubling; membrane potential differe... |
| MPED | minimum phototoxic erythema dose |
| MPD | Minimal phototoxic dose |
|---|---|
| HDRA | Histoculture Drug Response Assay |
| ADAP | AIDS Drug Assistance Program |
| ADE | Adverse Drug Event |
| ADR | Adverse Drug Reaction |
| phototoxic | Relating to, characterised by, or causing phototoxis. (05 Mar 2000) |
|---|---|
| phototoxic sensitivity | See: photosensitization. (05 Mar 2000) |
| dermatitis, phototoxic | A nonimmunologic, chemically induced type of photosensitivity producing a sometimes vesiculating dermatitis. It results in hyperpigmentation and desquamation of the light-exposed areas of the skin. (12 Dec 1998) |
| dose-response relationship, drug | The relationship between the dose of an administered drug and the response of the organism to the drug. (12 Dec 1998) |
| drug-drug interaction | The effects that occur when two or more drugs are used together. Such effects include changes of absorption in the digestive tract, changes in rate of the drugs' breakdown in the liver, new or enhanced side effects and changes in the drugs' activity. (09 Oct 1997) |
| anamnestic response | <immunology> Archaic term now replaced by such terms as secondary immune response, immune memory. (18 Nov 1997) |
| audiometry, evoked response | A form of electrophysiologic audiometry in which an analog computer is included in the circuit to average out ongoing or spontaneous brain wave activity. A characteristic pattern of response to a sound stimulus may then become evident. Evoked response audiometry is known also as electric response audiometry. (12 Dec 1998) |
| auditory brainstem response audiometry | An electrophysiologic measure of auditory function utilizing responses produced by the auditory nerve and the brainstem to repetitive acoustic stimuli. (05 Mar 2000) |
| biological response modifier | <pharmacology, oncology> A substance used in adjuvant therapy that takes advantage of the bodys own natural defense mechanisms to inhibit the growth of a tumour. (16 Dec 1997) |
| biological response modifiers | Substances that stimulate the body's response to infection and disease. The body naturally produces small amounts of these substances. Scientists can produce some of them in the laboratory in large amounts and use them in cancer treatment. Also called BRMs. (12 Dec 1998) |
| biphasic response | Two separate and distinct responses that are separated in time, immediate reaction to an antigenic challenge followed by a recurrence of symptoms after an interval of quiescence. (05 Mar 2000) |
| booster response | The response of the immune system to the second or subsequent occasion on which it encounters a specific antigen. (18 Nov 1997) |
| brainstem evoked response audiometry | An electrophysiologic measure of auditory function utilizing responses produced by the auditory nerve and the brainstem to repetitive acoustic stimuli. (05 Mar 2000) |
| galvanic skin response | A change in electrical resistance of the skin, occurring in emotion and in certain other conditions. (12 Dec 1998) |
| recruiting response | <neurology> The gradual increase to a maximum in a reflex when a stimulus of unaltered intensity is prolonged. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|